Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Jul 1 · above the Ichimoku cloud · RSI 48 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.2M | 0.00% | 1.25M | −29% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a LITS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 23, 2026 | Flynn James PDirector | Purchase at price 0.86 per share. | 25K | $21.39K |
| Dec 18, 2025 | Flynn James PDirector | Purchase at price 1.40 per share. | 70K | $97.70K |
| Dec 17, 2025 | Schornstein AlexanderBeneficial Owner of more than 10% of a Class of Security | Sale at price 1.37 per share. | 690.6K | $946.14K |
| Nov 18, 2025 | Flynn James PDirector | Purchase at price 1.88 per share. | 12.1K | $22.78K |
| Sep 29, 2025 | Flynn James PDirector | Stock Award(Grant) at price 2.54 per share. | 10K | $25.43K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.3 | -6.6 | 2.7 | -0.9 | -12.2 | -8.9 | 4.3 | 3.1 | 33.3 | -8.3 | −8.3% | ||
| 2025 | 15.9 | -10.2 | -14.5 | -6.8 | 9.8 | 10.3 | 108.5 | -5.6 | -50.2 | -13.6 | -9.6 | -30.2 | −46.3% |
| 2024 | -22.4 | -7.8 | -3.6 | -23.8 | -6.2 | 1.7 | 27.5 | -16.4 | -8.1 | 8.8 | -9.0 | -12.8 | −57.6% |
| 2023 | 20.8 | -24.1 | 4.5 | 10.7 | 51.3 | -14.5 | 7.4 | -24.8 | 31.8 | -2.7 | -10.0 | -5.5 | +20.8% |
| 2022 | -27.7 | 11.9 | -72.2 | -18.3 | -2.0 | 27.1 | -21.3 | 6.2 | -23.5 | -12.8 | 0.0 | -29.4 | −91.0% |
| 2021 | 22.3 | 16.1 | -8.5 | 6.4 | -21.1 | -1.0 | -5.3 | 3.7 | -1.4 | 2.2 | 19.5 | -20.8 | +1.1% |
| 2020 | -7.7 | -15.7 | -16.6 | 68.3 | 35.1 | 12.8 | -32.7 | -2.2 | 14.7 | -16.7 | 10.8 | -8.3 | +6.5% |
| 2019 | 2.3 | 6.7 | 6.6 | 2.3 | -8.9 | -12.6 | -32.0 | 0.6 | -1.8 | 7.7 | 8.3 | 26.5 | −6.1% |
| 2018 | 3.8 | 1.8 | -6.8 | 8.2 | 48.2 | 18.7 | -3.8 | 10.3 | 3.1 | -22.5 | -13.8 | -8.3 | +25.7% |
| 2017 | 4.2 | 12.7 | -4.1 | -1.9 | 41.5 | 6.2 | 20.1 | -8.0 | 1.5 | -2.2 | -14.5 | -6.2 | +45.8% |
| 2016 | -20.6 | -8.7 | 8.6 | 11.1 | 2.9 | -5.6 | 0.0 | 31.6 | -1.7 | -13.6 | 1.3 | -6.5 | −10.0% |
| 2015 | -7.7 | 49.5 | -69.6 | 11.2 | -4.5 | -10.0 | -8.8 | 16.7 | -13.7 | 14.0 | 1.7 | -12.1 | −62.5% |
| 2014 | 5.6 | 2.0 | 29.0 | -29.7 | -21.4 | 3.1 | 2.4 | 12.2 | -5.2 | 16.7 | -20.6 | -33.2 | −46.7% |
| 2013 | -28.6 | 49.0 | 15.8 | 3.4 | -5.8 | -15.1 | 6.5 | -1.7 | 50.8 | -28.7 | -1.2 | 1.1 | +14.4% |
| 2012 | -1.0 | -16.5 | -11.6 | -19.7 | 0.0 | -31.1 | 11.9 | -19.1 | 21.1 | -8.7 | 285.7 | -28.0 | +12.2% |
| 2011 | 205.2 | -41.2 | -9.2 | 1.9 | -16.8 | -23.9 | 112.7 | -32.3 | 0.7 | -10.1 | -19.5 | -2.8 | +7.2% |
| 2010 | -7.1 | -7.7 | -15.8 | 4.8 | -24.4 | -68.5 | -5.6 | -34.5 | 50.0 | -1.7 | -23.5 | 10.2 | −86.1% |
| 2009 | -32.9 | -17.0 | 2.6 | 37.5 | 50.9 | -37.3 | 46.2 | -2.6 | 31.1 | -29.9 | 10.3 | -6.7 | 0.0% |
| 2008 | -9.3 | -16.4 | 9.6 | 28.3 | -2.6 | -14.3 | -21.8 | 44.3 | -25.9 | -42.3 | -19.4 | -30.0 | −75.8% |
| 2007 | 37.6 | -4.3 | -3.0 | -10.0 | -10.8 | -2.2 | -3.9 | -5.1 | 11.4 | 9.0 | -18.8 | 4.7 | −5.6% |
No analyst coverage for this instrument.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. It is also involved in holding Litecoin tokens as a primary reserve asset. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.